FDA Authorizes Heart Monitor for CCP Virus Patients Being Treated With Hydroxychloroquine

The VitalPatch, bottom right, along with VitalConnect's Vista Solution program. VitalConnect via The Epoch Times

A heart monitor that will keep tabs on signs of possible heart-related side effects from hydroxychloroquine received emergency approval from the Food and Drug Administration (FDA).

The wireless remote monitoring system, called the VitalPatch, is the creation of California-based VitalConnect. The VitalPatch continuously monitors heart rate, heart rate variability, and other related metrics.